Management approaches for primary hepatic lymphoma: 10 year institutional experience with comprehensive literature review
PHL are an extremely rare subtype of NHL for which there is no clear treatment consensus. Primary hepatic DLBCL appears to be treated mostly with chemotherapy with good disease control. For indolent PHL, low-dose RT appears to have good overall disease control with minimal toxicity. Our RT data is limited by the short duration of follow-up for patients receiving RT compared to those who received chemotherapy, surgery or observation. However, our results are encouraging for the use of RT for appropriate patients with indolent PHL.
Authors
- Neil Ari Wijetunga (ORCID: https://orcid.org/0000-0002-8518-4691)
- Brandon S. Imber (ORCID: https://orcid.org/0000-0002-1281-5915)
- J El-Khoury (ORCID: https://orcid.org/0000-0003-4692-0841)
- Jennifer Ma (ORCID: https://orcid.org/0000-0001-8133-2282)
- Beatrice Fregonese (ORCID: https://orcid.org/0000-0003-3180-7176)
- Rémy Daou
- Joachim Yahalom
- Carla Hajj (ORCID: https://orcid.org/0000-0001-8774-1845)
- Josiane Bou Eid
Institutions
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- Saint Joseph University (LB)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-20
- DOI
- https://doi.org/10.3389/fonc.2025.1475118
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94